Published in Proc Natl Acad Sci U S A on October 01, 1972
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A (1977) 5.23
Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med (1975) 4.69
The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med (1980) 3.48
The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology (1973) 3.41
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med (1977) 2.87
Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest (1974) 2.81
The opsonic fragment of the third component of human complement (C3). J Exp Med (1975) 2.51
Serum-dependent phagocytosis of paraffin oil emulsified with bacterial lipopolysaccharide. J Exp Med (1973) 2.25
Acute inflammation. A review. Am J Pathol (1977) 2.06
Immune complexes in ulcerative colitis and Crohn's disease. Clin Exp Immunol (1977) 2.04
The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol (1975) 1.93
Immune complexes in acute and chronic liver disease. Clin Exp Immunol (1978) 1.93
Isolation and analysis of the mechanism of action of an inactivator of C4b in normal human serum. J Exp Med (1975) 1.86
A second case of human C3b inhibitor (KAF) deficiency. Clin Exp Immunol (1977) 1.50
Studies on the inhibition of C56 initiated lysis (reactive lysis). I. Description of the phenomenon and methods of assay. Immunology (1974) 1.49
The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b). J Exp Med (1975) 1.43
Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency. J Clin Invest (1975) 1.11
Serum-mediated leukemia cell destruction in AKR mice. J Exp Med (1973) 1.08
C3b inactivator deficiency with immune complex manifestations. Clin Exp Immunol (1982) 0.95
Activation of the alternative complement pathway of guinea-gip by liposomes incorporated with trinitrophenylated phosphatidylethanolamine. Immunology (1982) 0.91
The molecular basis of hereditary complement factor I deficiency. J Clin Invest (1996) 0.88
Three cases of factor I deficiency: the effect of treatment with plasma. Clin Exp Immunol (1988) 0.85
Correlations between serum factor B and C3b inactivator levels in normal subjects and in patients with infections, nephrosis and hypocomplementaemic glomerulonephritis. Clin Exp Immunol (1977) 0.84
Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clin Dev Immunol (2012) 0.83
Complement regulation in renal disease models. Semin Nephrol (2013) 0.80
Inhibition of C5 convertase by epsilon amino caproic acid (EACA): a limiting factor in the generation of C5a anaphylatoxin. Immunology (1978) 0.79
Recurrent infections in partial complement factor I deficiency: evaluation of three generations of a Brazilian family. Clin Exp Immunol (2006) 0.78
Formation in the presence of C3 nephritic factor (C3NeF) of an alternative pathway C3 convertase containing uncleaved B. Immunology (1976) 0.78
Membrane sialoglycolipids regulate the activation of alternative complement pathway by liposomes containing trinitrophenylaminocaproyldipalmitoylphosphatidylethaolamine. Immunology (1983) 0.78
Genetics of the complement system. J Med Genet (1975) 0.77
ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS. Anal Biochem (1965) 24.93
Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem (1966) 21.70
The C3-activator system: an alternate pathway of complement activation. J Exp Med (1971) 7.07
C3 proactivator convertase and its mode of action. J Exp Med (1972) 6.94
C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. J Immunol (1971) 5.41
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients. J Clin Invest (1967) 4.45
Three naturally-occurring inhibitors of components of complement in guinea pig and rabbit serum. J Immunol (1967) 3.86
Functional relationship of factor B in the properdin system to C3 proactivator of human serum. J Immunol (1971) 3.81
Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection. J Clin Invest (1970) 2.92
Deficiency of C3 inactivator in man. J Immunol (1971) 2.86
Partial purification of a serum inhibitor of C'1-esterase. J Biol Chem (1961) 2.69
Isolation and properties of a glycine-rich beta-glycoprotein of human serum. Biochim Biophys Acta (1970) 2.55
Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3). N Engl J Med (1970) 2.08
The properdin system and immunity. XIII. Assay and properties of a heat-labile serum factor (factor B) in the properdin system. Z Immun exp ther (1960) 1.87
Genetic aspects of the complement system. Adv Immunol (1971) 1.52
Genetic polymorphism in human glycine-rich beta-glycoprotein. J Exp Med (1972) 5.61
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
The enhancement of bacterial phagocytosis by serum. The role of complement components and two cofactors. J Exp Med (1969) 4.96
Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J Exp Med (1970) 4.92
Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients. J Clin Invest (1967) 4.45
Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J Exp Med (1970) 4.29
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
Human C'3: evidence for the liver as the primary site of synthesis. Science (1969) 4.17
Inherited structural polymorphism of the fourth component of human complement. Proc Natl Acad Sci U S A (1980) 3.97
Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med (1996) 3.89
Primary immunodeficiencies. Report of a World Health Organization Committee. Pediatrics (1971) 3.69
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology (1973) 3.41
Conglutinin and immunoconglutinins. Adv Immunol (1967) 3.16
Aberrations of suppressor T cells in human graft-versus-host disease. N Engl J Med (1979) 3.10
Genetic polymorphism of the third component of human complement (C'3). J Clin Invest (1968) 3.10
Homozygous deficiency of C3 in a patient with repeated infections. Lancet (1972) 3.04
The gamma globulins. 3. The antibody deficiency syndromes. N Engl J Med (1966) 3.03
Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection. J Clin Invest (1970) 2.92
Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity (1998) 2.92
N-WASP deficiency reveals distinct pathways for cell surface projections and microbial actin-based motility. Nat Cell Biol (2001) 2.91
Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry (1976) 2.89
Inherited structural polymorphism in human C2: evidence for genetic linkage between C2 and Bf. J Exp Med (1976) 2.89
Deficiency of C3 inactivator in man. J Immunol (1971) 2.86
Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest (1974) 2.81
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
Heterogeneity of "acquired" or common variable agammaglobulinemia. N Engl J Med (1974) 2.69
Statement on the nomenclature of human C4 allotypes. Immunobiology (1983) 2.66
The immunological specificity of a macrophage inhibition factor. Immunology (1970) 2.66
Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol (1972) 2.60
Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol (2000) 2.59
International system for human gene nomenclature (1979) ISGN (1979). Cytogenet Cell Genet (1979) 2.58
Isolation and properties of a glycine-rich beta-glycoprotein of human serum. Biochim Biophys Acta (1970) 2.55
The opsonic fragment of the third component of human complement (C3). J Exp Med (1975) 2.51
Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol (1996) 2.51
The physiological breakdown of the third component of human complement. Mol Immunol (1980) 2.50
Abnormalities of immunoregulatory T cells in disorders of immune function. N Engl J Med (1979) 2.48
Deficiency of a granulocyte-membrane glycoprotein (gp150) in a boy with recurrent bacterial infections. N Engl J Med (1982) 2.47
Implantation of a foetal thymus, restoring immunological competence in a patient with thymic aplasia (Digeorge's syndrome). Lancet (1968) 2.40
Reaction mechanism of the alternative pathway of complement fixation. Lancet (1973) 2.38
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol (1994) 2.36
Severe combined immunodeficiency and adenosine deaminase deficiency. N Engl J Med (1975) 2.35
Hereditary deficiency of the second component of complement (C'2) in man. J Clin Invest (1966) 2.32
Serum-dependent phagocytosis of paraffin oil emulsified with bacterial lipopolysaccharide. J Exp Med (1973) 2.25
Extended HLA/complement allele haplotypes: evidence for T/t-like complex in man. Proc Natl Acad Sci U S A (1983) 2.23
Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). Eur J Immunol (1984) 2.20
Cdc42 is required for PIP(2)-induced actin polymerization and early development but not for cell viability. Curr Biol (2000) 2.19
Hereditary deficiency of the second component of complement (C2) in man: correlation of C2 haemolytic activity with immunochemical measurements of C2 protein. Immunology (1970) 2.17
Increased susceptibility to infection in a patient with type II essential hypercatabolism of C3. N Engl J Med (1973) 2.17
The purification of specific antibody as F(ab')2 by the pepsin digestion of antigen-antibody precipitates, and its application to immunoglobulin and complement antigens. Immunochemistry (1971) 2.16
Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3). N Engl J Med (1970) 2.08
The interaction between human monocytes and red cells. Specificity for IgG subclasses and IgG fragments. J Exp Med (1970) 2.05
Identification and characterization of subpopulations of lymphocytes in human peripheral blood after fractionation on discontinuous gradients of albumin. The cellular defect in X-linked agammaglobulinemia. J Clin Invest (1973) 2.05
Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med (1982) 2.04
Polymorphism of the human complement C4 and steroid 21-hydroxylase genes. Restriction fragment length polymorphisms revealing structural deletions, homoduplications, and size variants. J Clin Invest (1986) 2.00
Hereditary angio-oedema: a review with particular reference to pathogenesis and treatment. Clin Allergy (1971) 2.00
Hereditary deficiency of the second component of complement (C'2) in man: further observations on a second kindred. J Immunol (1967) 1.98
A sedimentation pattern technique for measuring conglutination: its application to demonstrating immunoconglutinins to C'4. Immunology (1966) 1.95
The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol (1996) 1.94
The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol (1975) 1.93
Role of C3b in the breakdown of C3 in hypocomplementaemic mesangiocapillary glomerulonephritis. Lancet (1973) 1.93
The preparation and properties of alexinated intermediates that react with conglutinin. I. Guinea-pig complement. Immunology (1966) 1.92
Three rat monoclonal antibodies to human C3. Immunology (1980) 1.91
Immunofixation electrophoresis: a technique for the study of protein polymorphism. Vox Sang (1969) 1.88
The preparation and properties of alexinated intermediates that react with conglutinin. II. Equine, rabbit and human complement. Immunology (1966) 1.88
Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia. N Engl J Med (1977) 1.85
Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J Clin Invest (1971) 1.83
Selective gamma-g globulin deficiencies in patients with recurrent pyogenic infections. N Engl J Med (1970) 1.80
The relationship of glycine-rich -glycoprotein to factor B in the properdin system and to the cobra factor-binding protein of huan serum. J Exp Med (1973) 1.80
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest (1991) 1.79
Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clin Exp Immunol (1985) 1.76
Hereditary angioneurotic edema: a clinical survey. Pediatrics (1966) 1.75
The primary immunodeficiencies (1). N Engl J Med (1984) 1.74
Genetic polymorphism of human complement C4 and detection of heterozygotes. Nature (1979) 1.73
Molecular characterization of sialophorin (CD43), the lymphocyte surface sialoglycoprotein defective in Wiskott-Aldrich syndrome. Proc Natl Acad Sci U S A (1989) 1.73
Conglutinin binding polyethylene glycol precipitation assay for immune complexes. Clin Exp Immunol (1979) 1.71
Studies of hepatic synthesis in vivo of plasma proteins, including orosomucoid, transferrin, alpha 1-antitrypsin, C8, and factor B. Clin Immunol Immunopathol (1980) 1.69
Characterization of a human lymphocyte surface sialoglycoprotein that is defective in Wiskott-Aldrich syndrome. J Exp Med (1984) 1.68
The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol (1991) 1.68
Study of four new kindreds with inherited thyroxine-binding globulin abnormalities. Possible mutations of a single gene locus. J Clin Invest (1972) 1.64
Hereditary angio-oedema treated with E-aminocaproic acid. Br J Dermatol (1969) 1.64
Expression on blood cells of sialophorin, the surface glycoprotein that is defective in Wiskott-Aldrich syndrome. Blood (1987) 1.64